September 2015 Issue of The Ophthalmologist

Across medicine, far fewer clinical trials report positive results these days. Whether the demise of sharp scientific practices or the lack of low-hanging fruit – does it apply to ophthalmology?

Can amniotic stem cells suppress pathologic retinal neovascularization?

Gut microbes may be responsible for activating the T-cells that cause autoimmune uveitis

Like bevacizumab before it, ophthalmologists are trying off-label ziv-aflibercept (formulated for systemic use) in the eye. Masterstroke or madness?

A new study concludes that most surgical procedures used to treat optic disc pits are of no benefit – and may even be harmfu

A novel signaling pathway that leads to choroidal neovascularization has been identified – with obvious therapeutic potential

What if there was an imaging technique that could detect retinal disease processes before any structural damage had even occurred?

Direct visualization delivery of bevacizumab in pseudophakic eyes for the treatment of subretinal neovascularization

There’s currently an unmet need for effective interventions in early-stage retinal degenerative diseases – before vision is lost. Can three-nanosecond pulse laser therapy meet that need?

Looking at vitreous samples allows us to determine which proteins are involved in the disease process, and to what degree

AMD is the leading cause of blindness in developed countries, and the third-leading cause in developing countries.

The path to truly effective AMD therapies is long and requires us to recognize that it’s not a single disease entity: toil and teamwork are needed to triumph

Sitting Down With...Patricia A. D’Amore, Director, Howe Laboratory; Director of Research, Schepens EyeResearch Institute, and Charles L. Schepens Professor of Ophthalmology, Harvard Medical School, Massachusetts, USA.

Strength and durability in the real world